The Role of ADAM10/17 Activity Regulation in Aβ-induced Neuroglial Activation
CUI Boxiang1#, FANG Xingyue2#, LIU Qibing3, WANG Huanhuan1*
AD （Alzheimer’s disease) is a neurodegenerative disease that seriously affects life quality of elderly patients. The most important pathogenic mechanism of AD is the damage of nerve cells by Aβ (amyloid β protein). Aβ is cleaved by its precursor APP（ amyloid precursor protein) by β and γ secretase. α secretase can cleave APP to reduce Aβ production. Therefore, up-regulating the activity of α-secretase ADAM10/17 may become one of the therapeutic strategies of AD. The experimental data of this study confirmed that ADAM10/17 was not only involved in the cleavage of APP, but also involved in the activation of glial cells and neuroinflammatory reactions. ADAM10/17 may be involved in the modification and cleavage of glial inflammatory factors after translation. The results of this study provide a basis for the study of APP α-secretase activator. In the development of APP α-secretase activator, it should not be limited to the role of nerve cells, but also the involvement of glial neuroinflammatory in order to achieve effective elimination of adverse drug reactions.
CN
EN